所有图片(1)
About This Item
经验公式（希尔记法）:
C9H15N5O4S
CAS号:
分子量:
289.31
MDL编号:
UNSPSC代码:
12352107
PubChem化学物质编号:
NACRES:
NA.77
推荐产品
应用
米诺地尔硫酸盐(MXS)已用于研究其作为药物，对促肾上腺皮质激素释放因子过表达(CRF-OE)小鼠脱发的治疗作用。它也已用作某项检测的阳性对照，用于培养大鼠触须毛囊。
生化/生理作用
米诺地尔硫酸盐(MXS)是米诺地尔的内源性衍生物。水溶性更高，是强效的血管扩张剂。米诺地尔硫酸盐可治疗雄激素性秃发或男性型秃发。
特点和优势
该化合物由 Johnson & Johnson 开发。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单，请单击此处。
其他说明
米诺地尔的活性代谢产物。
警示用语：
Warning
危险分类
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
靶器官
Respiratory system
储存分类代码
11 - Combustible Solids
WGK
WGK 3
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
从最新的版本中选择一种：
分析证书(COA)
Lot/Batch Number
Pharmacological effects of drug conjugates: is morphine 6-glucuronide an exception?
G J Mulder
Trends in pharmacological sciences, 13(8), 302-304 (1992-08-01)
K D Meisheri et al.
The Journal of pharmacology and experimental therapeutics, 266(2), 655-665 (1993-08-01)
This study describes the in vitro and in vivo characteristics of a guanidine 4-morpholinecarboximidine-N-1-adamantyl-N'-cyclohexyl-hydroc hloride (U-37883A), as an antagonist of vascular ATP-sensitive K+ channels (KATP). In isolated rabbit mesenteric artery, the antagonistic effects of U-37883A (0.5-5 microM) were studied against
Nagendra S Ningaraj et al.
Cancer research, 63(24), 8899-8911 (2003-12-26)
Brain tumor microvessels/capillaries limit drug delivery to tumors by forming a blood-brain tumor barrier (BTB). The BTB overexpresses ATP-sensitive potassium (K(ATP)) channels that are barely detectable in normal brain capillaries, and which were targeted for BTB permeability modulation. In a
Michael J Shackcloth et al.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 34(4), 839-844 (2008-08-06)
Vasodilator strategies used to treat bypass grafts in the operating theatre, such as nitrates, phosphodiesterase inhibitors and calcium channel antagonists have a broad but short-lived effect against a variety of vasoconstrictor stimuli. Treatments that react irreversibly with proteins modulating vasoconstriction
K S Atwal
Journal of cardiovascular pharmacology, 24 Suppl 4, S12-S17 (1994-01-01)
KATP openers are recognized as having a therapeutic potential for the treatment of various cardiovascular and noncardiovascular diseases. However, the first-generation agents open KATP in a variety of tissues that limit their potential clinical utility. This review describes our studies
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门